Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
KPV
Anti-inflammatory α-MSH tripeptide fragment studied in cell and animal models for NF-κB inhibition.
Tier Cmed-high risk
02· Subject
BPC-157
Preclinical cytoprotective peptide studied for tissue repair and GI protection in animal models.
Tier Cmed-high risk
01 · At a glance
| Decision factor | KPV | BPC-157 | Thymosin Beta-4 |
|---|---|---|---|
| Primary fit | tissue repair & recovery and immune support comparisons | tissue repair & recovery research where you want a clear starting point | tissue repair & recovery and immune support comparisons |
| Evidence | Tier C | Tier C | Tier B-C |
| Risk | med-high | med-high | med-high |
| Experience level | intermediate | intermediate | intermediate |
| Budget tier | mid | mid | mid |
| Administration route | topical, subcutaneous | subcutaneous, oral | topical, subcutaneous |
02 · Use case & timing
| Decision factor | KPV | BPC-157 | Thymosin Beta-4 |
|---|---|---|---|
| Goal fit | Tissue Repair & Recovery, Immune Support, Skin & Hair | Tissue Repair & Recovery | Tissue Repair & Recovery, Immune Support |
| What users compare it for | Preclinical anti-inflammatory effects; skin/gut inflammation research. | Preclinical: angiogenesis markers, tissue repair signals, GI mucosal protection in rodent models. | Ophthalmic: improved corneal epithelial healing. Systemic: wound healing signals in preclinical models. |
| Onset timeline | Cell signaling endpoints are acute; clinical translation unknown. | Animal models: endpoints assessed over days to weeks (2-4 weeks in injury models). | Corneal healing studies: days to weeks; systemic repair claims are less well-timed. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | KPV | BPC-157 | Thymosin Beta-4 |
|---|---|---|---|
| Adverse effects | Limited direct human data. | Insufficient human data; immunogenicity risk flagged by FDA; impurity characterization concerns. | Human ophthalmic safety reported as acceptable in trials; systemic safety requires caution. |
| Contraindications | No data. | No established human contraindications (insufficient data). | Limited formal contraindication data. |
| Interaction notes | Unknown. | No robust human interaction map; avoid confident stacking claims. | Limited formal interaction studies; treat as unknown outside studied settings. |
| Regulatory status | Not approved | Not approved | Investigational |
| FDA flag | FDA status unclear | FDA compounding caution | FDA compounding caution |
| WADA status | Not listed | WADA S0 | WADA S2 |
04 · Age & monitoring
| Decision factor | KPV | BPC-157 | Thymosin Beta-4 |
|---|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54, 55-64 | No age guidance yet |
| Life-stage note | Not yet documented | Commonly researched by active adults for recovery, but still lacks validated human age-specific evidence. | Not yet documented |
| Monitoring burden | Not specified | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | KPV | BPC-157 | Thymosin Beta-4 |
|---|---|---|---|
| Typical cycle cost | $31.99 | $118.99 | $192.00 |
| Estimated monthly cost | $42.66 | $79.32 | $96.00 |
| Cost confidence | High confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | KPV | BPC-157 | Thymosin Beta-4 |
|---|---|---|---|
| Tracked vendor listings | 3 listings | 3 listings | 1 listing |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.